

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden	
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>KKR Genetic Disorder L.P.</u> (Last) (First) (Middle) <u>9 WEST 57TH STREET, SUITE 4200</u> (Street) <u>NEW YORK NY 10019</u> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>BridgeBio Pharma, Inc. [BBIO]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) <u>07/01/2019</u>	
		6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	07/01/2019		C		34,253,561	A	(1)	34,253,561	I	See footnotes(2)(3)
Common Stock	07/01/2019		P		2,647,100	A	\$17	36,900,661	I	See footnotes(2)(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Series B Preferred Units	(1)	07/01/2019		C			81,022,727	(1)	(1)	Common Stock	15,859,312	(1)	0	I	See footnotes(2)(3)
Series C Preferred Units	(1)	07/01/2019		C			36,246,893	(1)	(1)	Common Stock	8,215,295	(1)	0	I	See footnotes(2)(3)
Series D Preferred Units	(1)	07/01/2019		C			50,446,451	(1)	(1)	Common Stock	10,178,954	(1)	0	I	See footnotes(2)(3)

1. Name and Address of Reporting Person*
KKR Genetic Disorder L.P.
 (Last) (First) (Middle)
9 WEST 57TH STREET, SUITE 4200
 (Street)
NEW YORK NY 10019
 (City) (State) (Zip)

1. Name and Address of Reporting Person*
ROBERTS GEORGE R
 (Last) (First) (Middle)
2800 SAND HILL ROAD, SUITE 200
 (Street)
MENLO PARK CA 94025
 (City) (State) (Zip)

1. Name and Address of Reporting Person*
KRAVIS HENRY R
 (Last) (First) (Middle)

9 WEST 57TH STREET, SUITE 4200

(Street)

NEW YORK NY 10019

(City)

(State)

(Zip)

1. Name and Address of Reporting Person*

[KKR Management LLC](#)

(Last)

(First)

(Middle)

9 WEST 57TH STREET, SUITE 4200

(Street)

NEW YORK NY 10019

(City)

(State)

(Zip)

1. Name and Address of Reporting Person*

[KKR & Co. Inc.](#)

(Last)

(First)

(Middle)

9 WEST 57TH STREET, SUITE 4200

(Street)

NEW YORK NY 10019

(City)

(State)

(Zip)

1. Name and Address of Reporting Person*

[KKR Group Holdings Corp.](#)

(Last)

(First)

(Middle)

9 WEST 57TH STREET, SUITE 4200

(Street)

NEW YORK NY 10019

(City)

(State)

(Zip)

1. Name and Address of Reporting Person*

[KKR Management Holdings Corp](#)

(Last)

(First)

(Middle)

9 WEST 57TH STREET, SUITE 4200

(Street)

NEW YORK NY 10019

(City)

(State)

(Zip)

1. Name and Address of Reporting Person*

[KKR Management Holdings L.P.](#)

(Last)

(First)

(Middle)

9 WEST 57TH STREET, SUITE 4200

(Street)

NEW YORK NY 10019

(City)

(State)

(Zip)

1. Name and Address of Reporting Person*

[KKR Genetic Disorder GP LLC](#)

(Last)

(First)

(Middle)

9 WEST 57TH STREET, SUITE 4200

(Street)

NEW YORK NY 10019

(City)

(State)

(Zip)

Explanation of Responses:

1. Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all Series B Preferred Units, Series C Preferred Units and Series D Preferred Units (collectively, the "Preferred Units") of BridgeBio Pharma LLC (the "LLC") were exchanged for shares of Common Stock, par value \$0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of Preferred Units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, with a value implied by the IPO price of \$17.00 per share. The Preferred Units had no expiration date.

2. The securities of the Issuer are held by KKR Genetic Disorder L.P. KKR Genetic Disorder GP LLC, as the general partner of KKR Genetic Disorder L.P., KKR Management Holdings L.P., as the sole member of KKR Genetic Disorder GP LLC, KKR Management Holdings Corp., as the general partner of KKR Management Holdings L.P., KKR Group Holdings Corp., as the sole shareholder of KKR Management Holdings Corp., KKR & Co. Inc., as the sole shareholder of KKR Group Holdings Corp., KKR Management LLC, as the Class B common stockholder of KKR & Co. Inc., and Messrs. Henry R. Kravis and George R. Roberts, as the designated members of KKR Management LLC, may be deemed to be the beneficial owners having shared voting and investment power with respect to the shares described above. Each of Messrs. Kravis and Roberts disclaims beneficial ownership of the shares held by KKR Genetic Disorder L.P.

3. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the Reporting Persons are the beneficial owners of any securities reported herein.

Remarks:

KKR GENETIC DISORDER
L.P., By: KKR Genetic Disorder
GP LLC, its general partner, By:
/s/ Terence Gallagher, Name: 07/03/2019
Terence Gallagher, Title:

Attorney-in-fact for William J.
Janetschek, Chief Financial
Officer

KKR GENETIC DISORDER GP
LLC, By: /s/ Terence Gallagher,
Name: Terence Gallagher, Title: 07/03/2019
Attorney-in-fact for William J.
Janetschek, Chief Financial
Officer

KKR MANAGEMENT
HOLDINGS L.P., By: KKR
Management Holdings Corp., its
general partner, By: /s/ Terence
Gallagher, Name: Terence 07/03/2019
Gallagher, Title: Attorney-in-fact
for William J. Janetschek, Chief
Financial Officer

KKR MANAGEMENT
HOLDINGS CORP., By: /s/
Terence Gallagher, Name: 07/03/2019
Terence Gallagher, Title:
Attorney-in-fact for William J.
Janetschek, Chief Financial
Officer

KKR MANAGEMENT
HOLDINGS CORP., By: /s/
Terence Gallagher, Name: 07/03/2019
Terence Gallagher, Title:
Attorney-in-fact for William J.
Janetschek, Chief Financial
Officer

KKR MANAGEMENT
HOLDINGS CORP., By: /s/
Terence Gallagher, Name: 07/03/2019
Terence Gallagher, Title:
Attorney-in-fact for William J.
Janetschek, Chief Financial
Officer

KKR MANAGEMENT
HOLDINGS CORP., By: /s/
Terence Gallagher, Name: 07/03/2019
Terence Gallagher, Title:
Attorney-in-fact for William J.
Janetschek, Chief Financial
Officer

KKR MANAGEMENT
HOLDINGS CORP., By: /s/
Terence Gallagher, Name: 07/03/2019
Terence Gallagher, Title:
Attorney-in-fact for William J.
Janetschek, Chief Financial
Officer

KKR MANAGEMENT
HOLDINGS CORP., By: /s/
Terence Gallagher, Name: 07/03/2019
Terence Gallagher, Title:
Attorney-in-fact for William J.
Janetschek, Chief Financial
Officer

KKR MANAGEMENT
HOLDINGS CORP., By: /s/
Terence Gallagher, Name: 07/03/2019
Terence Gallagher, Title:
Attorney-in-fact for William J.
Janetschek, Chief Financial
Officer

KKR MANAGEMENT
HOLDINGS CORP., By: /s/
Terence Gallagher, Name: 07/03/2019
Terence Gallagher, Title:
Attorney-in-fact for William J.
Janetschek, Chief Financial
Officer

KKR MANAGEMENT
HOLDINGS CORP., By: /s/
Terence Gallagher, Name: 07/03/2019
Terence Gallagher, Title:
Attorney-in-fact for William J.
Janetschek, Chief Financial
Officer

KKR MANAGEMENT
HOLDINGS CORP., By: /s/
Terence Gallagher, Name: 07/03/2019
Terence Gallagher, Title:
Attorney-in-fact for William J.
Janetschek, Chief Financial
Officer

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.